System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jeffrey S Hyams is an expert in Gastroenterology at Connecticut Children's Medical Center (United States). As of October 2026, ScienceLeadR ranks Jeffrey S Hyams in the top 1% of experts worldwide for Crohn Disease, Colitis and Abdominal Pain. Jeffrey S Hyams has authored 714 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 1 of them ongoing. SLR score: 2,970 (community average: 125). How the SLR is computed.

LeadR Profile

Jeffrey S Hyams Connecticut Children's Medical Center United States
2 970 ScienceLeadR Reputation 2970

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Pediatrics - Nutrition - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

University of Connecticut

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 714

Citations

Citations: 35 815 1st author: 115 Last author: 173 Unique author: 41

Main journals

Gastroenterology 226
J Pediatr Gastroenterol Nutr 87
Inflamm Bowel Dis 62
J Crohns Colitis 51
J Pediatr 28

Best Journals

Gastroenterology 14
Nature 9
Lancet Gastroenterol Hepatol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Large-scale proteomics identifies a pretreatment Crohn's disease core proteome and a dynamic signature for anti-TNF response.
PMID 42899711 — crohn disease, biomarkers, inflammatory bowel diseases, proteomics, adalimumab, proteome, colitis, ulcerative, infliximab		Inflamm Bowel Dis20260
Microphysiological models of human gastrointestinal diseases.
PMID 42834084 — cells, pathology, organoids, gastrointestinal diseases		Nat Biomed Eng20260
Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics.
PMID 42582153 — tumor necrosis factor-alpha, crohn disease, neoplasms, biomarkers, necrosis, adalimumab, infliximab		Crohns Colitis 36020260
Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.
PMID 42566304 — serum, crohn disease, cohort studies, machine learning, inflammatory bowel diseases, metabolomics, precision medicine, therapeutics, colitis, ulcerative, child		Inflamm Bowel Dis20260
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease.
PMID 42503050 — crohn disease, pharmaceutical preparations, pharmacology, adalimumab, therapeutics, infliximab		Clin Pharmacokinet20260

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

N/A 6
Phase 3 4
Phase 2 2
Phase 4 2

By status:

Completed 11
Active not recruiting 2
Terminated 1

By type:

Interventional 10
Observational 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 11

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Clinical Imaging and Endoscopic Outcomes of Children Newly Diagnosed With Crohn s Disease
NCT05781152 — intestines, genes, blood, crohn disease, pharmaceutical preparations, drug monitoring, adolescent, inflammatory bowel diseases, adalimumab, therapeutics, colonoscopy, intestine, large, child, gene expression, infliximab		Phase 4Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS